The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRVS | -7.35% | +81.31% | +12.64% | -49% |
| S&P | +14.5% | +93.32% | +14.09% | +229% |
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | -38.1% |
| Market Cap | $308.46M | 170.9% |
| Market Cap / Employee | $9.95M | 0.0% |
| Employees | 31 | 10.7% |
| Net Income | -$8.00M | -87.7% |
| EBITDA | -$10.23M | -73.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.69M | -1.0% |
| Accounts Receivable | $0.09M | 145.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.73M | 0.0% |
| Short Term Debt | $0.36M | -49.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -58.61% | -21.7% |
| Return On Invested Capital | -75.83% | -24.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.89M | -7.5% |
| Operating Free Cash Flow | -$5.78M | -5.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.45 | 26.98 | 6.63 | 5.53 | 106.65% |
| Price to Tangible Book Value | 6.45 | 26.98 | 6.63 | 5.53 | 106.66% |
| Enterprise Value to EBITDA | -42.97 | -38.94 | -19.79 | -23.24 | 121.23% |
| Return on Equity | -200.5% | -174.9% | -100.1% | -68.7% | 52.89% |
| Total Debt | $0.35M | $1.12M | $1.15M | $1.08M | 54.71% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
